GlassScriptPhysician profile
Jessie M Cockrell
NPI 1285639302
$2,253.01
in general payments reported to CMS, 2019-2025
21 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $559 · 2021: $597 · 2022: $408 · 2023: $74.40 · 2024: $196 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $395.67 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $382.62 | 2021-2025 | |
| Lilly USA, LLC | $320.43 | 2020-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $191.96 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $169.31 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.21 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $114.57 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $103.08 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $72.49 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $70.52 | 2022 | |
| Pfizer INC. | $60.52 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $45.17 | 2024-2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $35.29 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.56 | 2022 | |
| Vyera Pharmaceuticals, LLC | $20.21 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.19 | 2025 | Xifaxan |
| Antares Pharma, INC. | $17.84 | 2022 | |
| Astellas Pharma US INC | $16.66 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $15.75 | 2019 | |
| Exact Sciences Corporation | $14.78 | 2024 | Cologuard Collection Kit |
| Venclose INC. | $10.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessie Cockrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.